Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Mark A. DiPaolo is an accomplished activist investor, corporate governance specialist, and seasoned public company director who currently serves as an Independent Director of OneIM Acquisition Corp., a special purpose acquisition company that successfully priced its $250 million initial public offering on January 13, 2026, and subsequently closed an upsized $287.5 million offering including over-allotments. DiPaolo was appointed to the OneIM board on January 13, 2026, alongside fellow independent director Antony Sheriff, as part of the SPAC's IPO structure led by CEO Ioannis Pipilis and CFO Grigorios Kapenis. The units began trading on Nasdaq under the ticker symbol "OIMAU," with each unit comprising one Class A ordinary share and one-sixth of one redeemable warrant. In his SPAC role, DiPaolo brings decades of experience in activist investing, corporate strategy, and board governance to guide the company's search for a suitable business combination target.
DiPaolo's primary professional affiliation is with Sarissa Capital Management LP, a registered investment advisor focused on improving company strategies to enhance shareholder value, where he has served as Senior Partner, Senior Managing Director, and General Counsel since 2013. He also held the role of Senior Managing Director at Sarissa Capital Acquisition Corp., another SPAC vehicle associated with the firm. Prior to joining Sarissa Capital, DiPaolo spent eight years from 2005 to 2013 as a senior member of Icahn Capital's management team, where he worked directly on the investing aspects of Carl Icahn's activist strategy. His career began in the legal profession as an attorney at Willkie Farr & Gallagher LLP, providing him with a strong foundation in corporate law and securities regulation that has underpinned his subsequent investing and governance career.
Across his career, DiPaolo has accumulated an extensive portfolio of board seats and leadership positions at publicly traded companies. He currently serves as Chairman of the Board at Syndeio Biosciences and previously served as Chairman of Innoviva, Inc., where he was also a director beginning around April 2019. He served as a director of Novelion Therapeutics Inc. from approximately August 2018 and was appointed as a director of Amarin Corporation PLC on February 28, 2023, a position he held until his resignation on April 18, 2025. His insider trading activity has been tracked across multiple companies including Innoviva, Sarissa Capital Acquisition Corp., Novelion Therapeutics, Amarin Corporation, and OneIM Acquisition Corp., with his most active year for acquiring shares being 2023, when he executed six transactions totaling 629,174 shares. His estimated net worth based on reported shareholdings is approximately $3.06 million.
DiPaolo holds a B.A. degree from Fordham University and a J.D. degree from Georgetown University Law Center. He is based in Greenwich, Connecticut, and was born in November 1970. His deep expertise in corporate strategy, business development, innovation, and organizational development, combined with his extensive experience navigating activist campaigns and board-level governance at both pharmaceutical and diversified companies, positions him as a valuable independent voice on the OneIM Acquisition Corp. board as the SPAC pursues its acquisition mandate.
This record is keyed to SEC CIK 0001669816 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 7 institutional-holder rows on these vehicles, under 5 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.